🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Teleflex Incorporated (TFX)
NYSE: TFX · Real-Time Price · USD
165.85
+6.30 (3.95%)
Nov 18, 2026, 4:00 PM EST - Market closed
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

Integration issues eased by Q3, supporting a broader interventional portfolio and plans for continued quarterly improvement toward a solid 2027. Management expects ~23% operating margin within 12 months of the final divestiture, with cost-out and lower financing costs supporting improvement.

Matt Taylor
Analyst, Jefferies

Thanks, everybody, for joining us. I'm Matt Taylor, the U.S. Medical Supplies and Devices Analyst here at Jefferies, and I'm really pleased to be joined by Teleflex management, including Jason Weidman, the CEO, and John Deren, and also Larry Keusch, here in the room. We'll have about 25 -minutes for Q&A. Maybe, I'll kick things off, Jason.

Jason Weidman
CEO, Teleflex

Sure.

Matt Taylor
Analyst, Jefferies

Pleasure to host you. You've been in the seat for about five months, coming from a cardio background and into a company that has some big cardio aspirations. Would love to get your assessment in the initial five months. What attracted you to Teleflex? Maybe talk about that specific opportunity, too, in cardio now with the BIOTRONIK acquisition complementing what we already had from the legacy Vascular business.

Jason Weidman
CEO, Teleflex

Yeah, sure. So, look, looking at the opportunity before I started, I was interested and very intrigued by the portfolio transformation that was going on, the opportunity to kind of shrink and focus, and really, with what we're going to be left with here at the RemainCo when all that transformation is done is three focused divisions. I thought that was a good platform from which to grow. I like the combination with bringing in BIOTRONIK VI to the legacy Teleflex business. Those portfolios work really well together. I could see that from the outside coming from that space. Coming in now, five months, I've really spent a lot of time diving in, trying to really better understand our products, the therapies, how the company works. I've been to all of our sites, many of them more than once, talked to employees all over.

I'd say at the end of all of that, first and foremost, it just really reinforced my conviction of what we have here. We've got great products, market-leading positions in a lot of key categories, strong brands, and so that, and really good foundation from which to grow. We've got great employees who are hungry for change and want to do things differently. The other thing I would say is it's really kind of colored where I think we need to go going forward. Really got three priorities. The first is really focused on foundational things. We got a lot of stuff we're still finishing off. Obviously, we got the divestitures and the ensuing work with that. We've got to finish the integration of BIOTRONIK VI into Teleflex. From there, we've got some work on our operating model.

We're doing some things to simplify our operating model, making some major changes to move to a global business unit, then we're going to elevate our growth profile. Those are kind of the three main priorities going forward.

Matt Taylor
Analyst, Jefferies

Yeah, those are probably three great things to double-click on. Maybe we could start by just talking about the progress with the divestitures. Remind us of the timeline with the second one, then your goals for capital deployment alongside that.

Jason Weidman
CEO, Teleflex

Sure. With the divestitures, as a reminder, we had two different divestitures that happened. One was with our OEM business that closed already. That was about three-quarters of the proceeds, so that's done already. We still have the divestiture of the Acute Care and Interventional Urology business that's in process. Where we are specifically with that right now is that we had a second request from the FTC earlier this year. It just relates to a small product overlap with the buyer's portfolio. It's very defined and manageable. It's not a big issue. This is a buyer-driven process, so they've been working on a remedy, making great progress. We've supported them along the way. We're both actively driving to get that closed by the end of this calendar year.

But as we talked about on our last call, as we're working with the unknowns of a regulatory process, it could go a little bit into 2027, but we're still super confident that it's going to close. It's just kind of working through the days that are left in the calendar. In terms of the use of those proceeds, we had committed to $1 billion in share buybacks, $800 million in debt reduction already with the close of OEM, and other things. We've finished $600 million of the $1 billion of the share buybacks, and we've paid down $700 million in debt. Kind of the remaining $400 million and $100 million is what we would look to do as we do the final divestiture.

Matt Taylor
Analyst, Jefferies

Can you talk about your pro forma leverage and leverage goals, and what this will mean now with the refreshed balance sheet to be able to do some type of—

Jason Weidman
CEO, Teleflex

Yeah, I mean, we have—

John Deren
CFO, Teleflex

Yeah, I mean, right now, leverage is pretty low at 1.4x. I think we'll likely, in the near term, stay well under two is my thoughts. I mean, obviously, we have to get through the final integration of BIOTRONIK, the disposition. I think this year, we don't see —if a great asset comes our way that we have to buy, we'd likely do something. But I think right now, we want to focus on getting the business stabilized, get the acquisition complete. So, I would say likely you see us stay under 2x in the near term. Yeah, we committed to stay under 3x through all the turmoil, and we did that.

I think we've had a lot of opportunity to pay down the debt a little bit ahead of schedule, as well as we've done some buybacks ahead as well, so that's been incrementally useful too.

Matt Taylor
Analyst, Jefferies

Great. Maybe we will talk a little bit about the BIOTRONIK integration.

Jason Weidman
CEO, Teleflex

Sure.

Matt Taylor
Analyst, Jefferies

You talked about a few things that are happening, need to happen for that to work through and get back on track. Can you talk about the progress through order to cash, hiring folks, and getting the—

Jason Weidman
CEO, Teleflex

Distributors?

Matt Taylor
Analyst, Jefferies

—distributor transitions? Yep.

Jason Weidman
CEO, Teleflex

Yeah. In my first earnings call, we kind of brought this up where we were seeing some slowness, or the integration was going slower than we expected. It is really those three things that we isolated some of the challenges to. If I kind of break them down. On the order to cash side, at this point, we have transitioned about 90% of the legacy BIOTRONIK customers onto Teleflex ordering systems. When you do that type of change, no matter how well the actual systems part of it goes, there can be some customer disruption. They can be confused, no matter how much training you do, et cetera. We experienced some of that disruption as we went through that, particularly in Q2.

To give you an example, in Europe, where a huge portion of that BIOTRONIK business was, we had about 7% of orders that were just going to the wrong place, into Neverland. We had to track down and try to. That is a huge number that you do not want to happen. As we worked through Q3 and got tied up those loose ends, we had that far under 1%, so we got that under control. We feel pretty good about that. We got about 10% of customers left across the globe that we have to transition, but we feel good about the staging that will happen there. Second area was distributors and the transition with distributors. We inherited a sizable book of indirect business from BIOTRONIK VI.

Obviously, when that first comes in, you are inheriting the other company's actual distributors and their contracts. When that happens, you do not necessarily have full visibility to how they are going to order, nor do they have a huge incentive to work really collaboratively with you, if they are not going to be the long-term distributor. For those first couple of quarters, before we had transitioned things over to Teleflex, it became a challenge for us. At this point though, as we finished Q3, 87% of the indirect business now is running through either our distributors, legacy Teleflex distributors, and/or we have converted them to Teleflex contracts. Now at this point, we have that clear line of sight to what is going on with the distributors, their ordering patterns, and are working much more collaboratively with them. We understand where that is going.

We have turned that corner of where that distributor business had been coming down since the acquisition, and now I feel strongly that that will be on the upswing now. The last piece was just really on sales force transition, and as we brought the sales forces together, we had a lot of open heads, particularly in the United States. This was really that, as you bring these two very complementary portfolios together, you had people on both sides that were used to selling the opposite type of product, and a lot of them were going to be really great at selling the whole bag, and we found a lot of them were only going to be great at selling their old portion of the bag, and that frankly was unacceptable, and we needed to find new people.

We had a lot of open spots, but by the end of Q3, those had decreased by almost two-thirds. I would say probably even more important to me is that the quality of people that we are getting in is excellent now. I think I mentioned this on our Q3 call that we are starting to get cold calls from some of the best people in the industry, even when we do not have spots open. I think that says a lot to what we have in our bag, what people see in leadership, and where we are going and the potential.

Matt Taylor
Analyst, Jefferies

Great. One interesting comment you made before was, looking at it from the outside and coming from Medtronic—

Jason Weidman
CEO, Teleflex

Yeah.

Matt Taylor
Analyst, Jefferies

—you said these things coming together was kind of an interesting play. I would love for you to just explain what Teleflex had in the legacy business, and what BIOTRONIK brings to that, and where there is a lot of synergy having that bag together.

Jason Weidman
CEO, Teleflex

Yes, sure. In interventional procedures, in the interventional space, the first part of a procedure is gaining access and getting to the lesions to be treated. Particularly as patients and lesions to be treated have gotten more complex over time, there is a lot of specialized tools that are needed to actually access and do the treatment. Legacy Teleflex was excellent at that, and they are very well-known. They have created some of the product categories that are used by almost all physicians around the world. Very, very good at that. Teleflex did not actually have the treatment devices, and that is where BIOTRONIK VI came in, where they actually had the treatment devices. Same procedure, it is increasing your share of wallet, same rep could be in that procedure and sell that whole continuum of devices. That is how those two pieces come together.

I would say the one thing I would note with the treatment devices from BIOTRONIK VI is that when I was at Medtronic, honestly what we used to always say is, we are really glad that BIOTRONIK's sales and marketing is not better because their products are really good. That was one of the things that excited me is if we put these portfolios together, we know we have really great products across the board. What can we do with that when you have a complete portfolio and you put the right leadership behind it? We just brought in new leadership in the Interventional business, and what can we really drive? I am excited to see what we can do.

Matt Taylor
Analyst, Jefferies

Yeah. Maybe talk about that talent aspect too. It is interesting that you are getting these cold calls and a lot of good talent in. Of course, you are a cardio guy, so you have a lot of relationships, I am sure, to be able to leverage that too. Our old friend Sean Salmon is on the board, so I know he knows a lot of cardio folks. Maybe just speak to what do you think is really attracting the talent? How are you using your networks to leverage and get talent into the organization?

Jason Weidman
CEO, Teleflex

Yeah, I think first and foremost, I think when people are looking at an organization, they want to see a prospect for the future. In the interventional business, there is this really nice complete bag. I think one of the challenges Teleflex Interventional has or has had since the combination with VI is that a lot of people just didn't know that it had come together and what that portfolio looked like. So, this is an awareness issue that we've been addressing, not just with customers, but also with potential candidates. A lot of the people I've talked to, as people have come forward, were kind of even shocked to understand all of the pieces in the portfolio, and then they get excited about, particularly if they're in the selling organization, they get excited about being able to sell those types of aspects in the bag.

I think just the other part, again, is do they have somebody they can get behind and that they feel like they'd be excited to work for? Particularly Jason Fontana, who we brought in to run that business, who came in in September, he has a really strong following of people that have worked for him in the medical device industry for 20+ years. I honestly, I think you'd be hard-pressed to find anyone that has better customer relationships than him. I mean, he is as steeped in customer relationships as anybody.

Matt Taylor
Analyst, Jefferies

Great. So I guess putting all that together, and having gotten through a lot of the distributor issues, the order to cash, now hiring, maybe talk a little bit about the outlook for that business, and what kind of improvements in growth could we see in the coming quarters? Ultimately, what is your goal for that division for growth?

Jason Weidman
CEO, Teleflex

Yeah, I think right now our goal is to see continuous improvement every quarter. We saw some improvement in this last quarter, but my expectation is we continue to do that. First and foremost, we want to set ourselves up for a solid 2027, then we want to be able to get it back to market growth, then set it up for long-term success. I think, again, we're in a really great position here because, as we just talked about, we have these great products, we have the right leadership in place, then you can then look at what are our vectors for growth within that business as we get that foundation shored up. We have a lot of room for share gain, particularly in those treatment devices. You combine that with our portfolio, pull through the treatment devices.

Second area, second vector of growth within Interventional, it's a huge opportunity internationally, more so than a lot of other med tech segments. A huge percentage of the PCIs or coronary treatments, interventional treatments, are done outside the U.S., so there's a lot of room for us. We're underweight internationally, or outside of Europe and the U.S., so there's a lot of room for us there. The third growth vector is really going to be new product introductions. We've got a rich pipeline of things coming out, big and small, and we're excited about that.

Matt Taylor
Analyst, Jefferies

Yeah. Maybe one of the bigger ones we could touch on is Freesolve. There's been some buzz around the idea of leaving nothing behind. This is a stent that resorbs after some time.

Jason Weidman
CEO, Teleflex

Yep.

Matt Taylor
Analyst, Jefferies

Early data looks pretty good. Maybe you could talk a little bit more about it, the data release next year, and when that could become a commercial reality.

Jason Weidman
CEO, Teleflex

Yeah, sure. So, maybe taking a step back so that everybody understands what Freesolve is. When you are treating a coronary artery, you have a blockage, and stents were invented originally because you used to clear it with a balloon, but then a huge percentage of the time it would just recoil back. So you need some scaffolding there to keep that blockage open, but then you only really need it there for about 6-12 months, and then the vessel remodels. If it was gone at that point, it would be totally fine. So for decades, the dream has been to have a stent or a scaffold go in, and then disappear when you do not need it anymore. So we have seen nothing left behind, drug-coated balloons come out, and frankly, that is just because absorbable scaffolds have not worked yet. You still have those acute closure issues.

If you look at those trials and look at the amount of times there is a crossover and you end up having to put in a permanent stent, it is about 10% of the time. So, the world would still prefer to have an absorbable scaffold in the ideal state. That has been tried many times. For 30 years, people have tried. Fundamentally, the challenge in this is that great idea, but it has been difficult technically, and almost every other attempt has been with these absorbable scaffolds that have been made out of plastic. So, when you have a plastic scaffold, it does not have the mechanical properties of a metal. It does not have the radial strength. It is hard to deliver, it is hard to implant, and they take two to three years to absorb. Fundamentally, that resulted in poor clinical results.

With Freesolve, what we have is an absorbable metal. So we are unique in that standpoint. It has taken over 20 years to develop, so it is a huge technological leap. When you put this in front of a physician, they will look at it and say, this is completely different than what Abbott was trying to do with Absorb. It is much more, like if you had a standard stent and Absorb and Freesolve looks like the standard stent, not like an Absorb. It has the mechanical properties of a metal stent. It delivers great, it implants like a normal stent, has the radial strength of a normal stent. So we have had these, as you said, intriguing and really positive early results in our single arm clinical trial, but we have to see how this performs versus a drug-eluting stent in a randomized fashion.

So, we will get our first readout of that in about a year. So, if we are sitting in these chairs next year, we can talk about that. We will have the data at that point on the first 2,000-patient randomized trial. Then, we have a second pivotal randomized trial that is ongoing in the U.S.

Matt Taylor
Analyst, Jefferies

Great. I want to talk a little bit more about your innovation. One of my jokes is I think Teleflex is known for really cool product names. You've got RePlas, EZPLAZ coming out. I also like the TrapLiner catheter is a good one.

Jason Weidman
CEO, Teleflex

Yeah.

Matt Taylor
Analyst, Jefferies

But let's talk about EZPLAZ and the opportunity there. It's been kind of a long time coming.

Jason Weidman
CEO, Teleflex

Yeah.

Matt Taylor
Analyst, Jefferies

Very unique product, so I'd love for you to expand on what that is, why it's so unique, and maybe talk about this initial $200 million opportunity that you've identified.

Jason Weidman
CEO, Teleflex

Yeah, sure. EZPLAZ is freeze-dried plasma, and I would say, to be honest, coming into Teleflex, I did not know a lot about it, and this is one of the more exciting things for me as I've come in to learn about and really dive in and understand. One thing of note is that people have been trying to develop freeze-dried plasma for literally almost 100 years. And there have been other attempts at it. There have been things that have been out there that ended up not working. It's a very, very challenging technical problem, so really proud of our team to get this through, and now become the first FDA-approved device for freeze-dried plasma. So what you have is this device that can be stored or product that is stored at room temperature.

You add saline to it can be reconstituted literally in a couple of minutes. We do have a 12-month shelf life on it now. It is also in a plastic bag, which may sound kind of like not exciting, but actually that is like one of the wonders of the development is that other people developing freeze-dried plasma, they have only been able to freeze dry it into a glass container, which as you can imagine, in trauma situations, in military situations, you do not want to be carrying around a glass container of plasma. It is better to have it in a flexible bag. So we have had tremendous feedback from all sorts of potential customers and excitement around that. As you said, we recently have said that in the U.S., we think that the market opportunity is at least $200 million in the long term.

This is a combination of government military applications, as well as civilian applications. It is a market development play. It will take time for this to play out. We see our first focus and the vast majority of our current capacity is probably going to go to that military government use, and that is where we have been focusing our time in the short term, as we are also starting to parallel pass some early efforts with the early adopters in the civilian segment.

Matt Taylor
Analyst, Jefferies

Great. Maybe with the few minutes we have left, I want to talk a little bit about numbers. I know you are not going to guide on 2027 today, but maybe let us talk about some of the moving parts, because we have still to close the second deal, so that is going to impact the timing of capital deployment, certainly. But, you have talked about this underlying margin sort of pro forma of about 23%.

Jason Weidman
CEO, Teleflex

Yeah.

Matt Taylor
Analyst, Jefferies

With the ability to build from there. What are the other puts and takes that people should think about for 2027?

Jason Weidman
CEO, Teleflex

Yeah. Why don't I just start at a high level, and then I can—

John Deren
CFO, Teleflex

Sure.

Jason Weidman
CEO, Teleflex

You welcomed it since you've been really quiet. We'll let you take it. We have talked about that we would expect, as we head into 2027, a meaningful improvement in our financials. I would say that it also should be much more representative of what we think the company will be like going forward. So, we will have expanded margins, and we would say within that first 12 months of closing that last divestiture, we would expect that to be around 23% from operating margin standpoint. Our interest expense will be lower. We'll have lower share count. So, we'll see this meaningful step up in EPS over time. I think that that, in a nutshell, at a high level, we're encouraged and excited about 2027. There's a lot of things that I would say we should be looking for as we enter into 2027.

When do we exactly close that last divestiture? From an opportunity standpoint, obviously, we're looking for continued improvement in the Interventional business, like we talked about, that continuous improvement. EZPLAZ will be a contributor next year. All of those things are moving in our direction. I don't know if you have any—

John Deren
CFO, Teleflex

I think you got most of it there. I mean, the 23% expansion is really the TSAs, MSAs, and additional cost-out programs. As some of those TSAs and MSAs roll off, the cost-out programs increase and take up that slack. Keep in mind, I mean, that to us is the baseline as the business has an opportunity to improve when you get some leverage in the P&L. I would hope to see that margin continue to increase.

Matt Taylor
Analyst, Jefferies

Got you. Maybe just talk about the level of confidence that you have in the cost-out programs basically matching the stranded cost.

John Deren
CFO, Teleflex

Yeah. Listen, you're never going to find yourself with the perfect line, right. I mean, it's probably going to be a little lumpy. I'll be honest with you, we've had a lot of success, excuse me, in 2026, not just identifying the additional cost out that we need to identify, but also getting to some of the programs a little earlier than we expected. So, I'll have a little bit of both going on for a while, then sometimes there'll be some lumpiness. But as we talked about, when we look at the full 12 months, we kind of see that 23%. So there'll be some lumpiness to that, but it'll be overall consistent for like an annual basis. Then, we have a lot of confidence in the ability to kind of cost out there.

Frankly, over the years, as we've done manufacturing moves, other restructuring programs, it's something we've actually been pretty good at, and we've been pretty consistent in delivering, so.

Matt Taylor
Analyst, Jefferies

Yeah. You've also said generally you expect to be able to expand margins beyond that in the future without giving specific goals yet. But, maybe you could talk about sort of the main sources of that margin expansion in 2028 and beyond. I would think growth and growth in cardio is going to be a big one. But what are the other sources of margin expansion, and what kind of expansion can we expect?

John Deren
CFO, Teleflex

Yeah, I mean, listen, I think when we talked about the separation and the strategic goals, we talked about mid-60s for gross margin. Then tariffs came in, and they ate up a little bit of that, right. So that's maybe 300 basis points ate up the gross margin. So we kind of see ourselves in that kind of a low -60%, and it'll bobble in particular quarters. We have some products that are much greater gross margin than the average, and some that are frankly less, right. And so depending on the outperformance, that mix will change quarter- over- quarter. But, I kind of see the business in that similar margin profile, if you will. The opportunity as you grow, though, will be on the other fixed costs, and that will help the op margin improve as well.

As the top line improves, even if the gross margin stays the same, we should help leverage that op margin even further. The original, the first cut really is that cost out, right. As we take that cost out in the next two years, that's where your big expansion comes from initially, and then it's P&L leverage, as I said.

Matt Taylor
Analyst, Jefferies

Maybe one to add on one of my favorite questions is just what's your tariff strategy? I've been in the backyard looking for your plane to go into Mar-a-Lago. I haven't seen it yet. But what are some—

Jason Weidman
CEO, Teleflex

We don't have a plane anymore. That was part of our cost out.

John Deren
CFO, Teleflex

Yeah, we did take out the plane. Listen, it is hard to know what the administration may consider doing next, these 232 investigations, what is going to come of it. Right now, we are thinking about $30-ish million for next year. The big strategies we have, we have taken a lot out of the USMCA because we have a lot of manufacturing in Mexico. We have done most of what we can do there, honestly. There is still a fair amount of components that need to come from other places. Unfortunately, I think we have kind of hit where we expect to be from USMCA. Are we going to move manufacturing back to the United States? Not likely. Deals like BD, I do not think you are going to see that from Teleflex. Frankly, the leverage we still get out of operating in a low-cost region is significant, even with the tariff.

Matt Taylor
Analyst, Jefferies

Great. Well, guys, thanks so much. Thanks for your time. Thanks, everybody, for your interest in Teleflex.

Jason Weidman
CEO, Teleflex

Yeah. Thank you.